1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1) : a single-arm, multicentre phase 1b/2 study
(
- Contribution to journal › Article
-
Mark
Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study
(
- Contribution to journal › Article
- 2023
-
Mark
Improving access to surgery for childhood cancer
(
- Contribution to journal › Debate/Note/Editorial
- 2021
-
Mark
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
(
- Contribution to journal › Article
-
Mark
Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer : recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group
(
- Contribution to journal › Scientific review
-
Mark
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer : an open-label, randomised, phase 2 trial
(
- Contribution to journal › Article
- 2020
-
Mark
Sustainable care for children with cancer : a Lancet Oncology Commission
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5) : a 2-year interim analysis of a multicentre, prospective, cohort study
(
- Contribution to journal › Article
-
Mark
One-view breast tomosynthesis vs two-view mammography : a methodological issue – Authors' reply
(
- Contribution to journal › Letter
-
Mark
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN) : a randomised, placebo-controlled, phase 3 study
(
- Contribution to journal › Article